Study finds long-acting shot helps women avoid HIV infection


Researchers are stopping a study early after finding that a shot of an experimental medicine every two months worked better than daily pills to help keep women from catching HIV from an infected sex partner.

The news is a boon for AIDS prevention efforts especially in Africa, where the study took place, and where women have few discreet ways of protecting themselves from infection.

Results so far suggest that the drug, cabotegravir, was 89% more effective at preventing HIV infection than Truvada pills, although both reduce that risk.

The results mirror those announced earlier this year from a similar study testing the shots versus the daily pills in gay men.

Cabotegravir is being developed by ViiV Healthcare, which is mostly owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited. The study was sponsored by the U.S. National Institutes of Health, the Bill and Melinda Gates Foundation and ViiV. The drugs were provided by ViiV and Truvada’s maker, Gilead Sciences.

“This is a major, major advance,” said Dr. Anthony Fauci, the top infectious disease doctor at the NIH. "I don’t think we can overemphasize the importance of this study.

It promises HIV prevention help to young women, “those who need it the most,” he said.

Young women may be twice as likely as men to get HIV in some areas of the world, according to one study leader, Sinead Delany-Moretlwe of the University of the Witwatersrand in Johannesburg, South Africa.

“They need discreet options ... without having to negotiate with their partners” to use measures such as condoms, said Deborah Waterhouse, of ViiV.

The study involved more than 3,200 participants in seven African countries who were randomly assigned to get either the shots every two months or daily Truvada pills. Independent monitors advised stopping the study after seeing that only 0.21% of women receiving the shots caught the AIDS virus versus 1.79% of women on the pills.

There were more side effects, mostly nausea, with the daily pills.

Cabotegravir's makers are seeking approval from regulators to sell it for this purpose, and Truvada already is widely used.

“The urgent work now” is to make all prevention medicines affordable and more widely available, said Mitchell Warren, who heads AVAC, formerly known as the AIDS Vaccine Advocacy Coalition, a nonprofit focused on prevention efforts that had no role in the study.

Condoms remain widely recommended because they help prevent a host of sexually spread diseases, not just HIV.

“People need choices for HIV prevention,” and this gives a new option, Warren said in a statement.

© Copyright 2020 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.

©2020 GPlusMedia Inc.

Login to comment

Cost of a shot compare to pills ?

And it is not a scientific study. It is a practical study only.

If it just limit spreading over time, it is just leaving more time to live but not avoid catching it in the long term...

-1 ( +1 / -2 )

And it is not a scientific study. It is a practical study only.

That makes no sense, methods is what make a study scientific or not, a practical application is irrelevant for this, the trial is HPTN 084, a "phase 3 double blind safety and efficacy study of long-acting injectable Cabotegravir compared to daily roal TDF/FTC for pre-exposure prophylaxis in HIV-uninfected women."

This would mean is a scientific study no matter how you want to define it.

And no, what is spreading over time is the dosing, the effect is the same, preventing infection. The inyectable version is not yet priced but the Truvada pills are about $2,000 a month, so it is quite easy to make it cost effective, especially taking in account adherence to the method which is a problem for all daily oral formulations. It is also easier to include in medical insurance plans because it can be controlled more closely and is less susceptible to be abused.

1 ( +2 / -1 )

Login to leave a comment

Facebook users

Use your Facebook account to login or register with JapanToday. By doing so, you will also receive an email inviting you to receive our news alerts.

Facebook Connect

Login with your JapanToday account

User registration

Articles, Offers & Useful Resources

A mix of what's trending on our other sites